Partnering opportunity

Multicomponent nanoparticles for cell transfection and selection

Summary

A Spanish research centre has developed innovative non-viral gene delivery nanoparticles for cell transfection and selection. They seek license, research cooperation or technical cooperation agreements with Biotech and Pharma companies.

Partner sought

Patent ready for licensing-out via license agreements. The research center is seeking industrial partners, either Biotech or Pharma, to: - enter into preclinical R&D collaboration (in vitro and/or in vivo drug testing) - Further development until clinical proof-of-concept Besides, the research center is looking for R&D institutions to establish tecnhical cooperation agreements or research cooperation agreements.

Description

This research networking center gathers some of the main Spanish research groups in biomedicine, located in more than 100 institutions as universities, hospitals and technological centers distributed around the country. Gene therapy has arisen as a pioneering technique to treat or improve the health condition of the patient by modifying the patient’s cells genetically (direct employment of nucleic acids as medicine). The major historical problem is to develop efficient and safe systems for the delivery of therapeutic genes (modified DNA) into the target cells. The delivery of modified DNA into cells (transfection) can be accomplished by multiple methods (vectors). The present vectors used for gene therapy are broadly classified as Viral vectors (recombinant, biological nanoparticles), Non-viral vectors and engineered vectors (Naked DNA, inorganic nanoparticles, dendrimers, oligonucleotides). The efficiency of transfecting host cells is relatively high with viral vectors compared to non-viral methods, however, the major advantage of using non-viral vectors is its bio-safety. Non-viral vectors have drawn significant attention due to its less immunotoxicity. Use of non-viral vectors in clinical trials has increased in the last years while that of viral vector saw significant decrease. Advances in efficiency, specificity, gene expression duration and safety led to an increased number of non-viral vector products entering clinical trials. Unfortunately, none of the currently available non-viral vectors fulfills ideal vector properties. This has led to research focus on suitable ideal vector delivery system. They are looking to establish license, research cooperation or technical cooperation agreements.

Advantages and innovations

The new nanoparticles enhance cell transfection efficiency, promotes particle endocytosis for delivery of the target polynucleotide and facilitate rapid and massive separation of particle-containing cells by application of a strong magnetic field. The new multicomponent particles enhance the transfection efficiency on different cell types. The specific components of the nanoparticle are: a superparamagnetic metallic oxide, certain poly(beta-amino ester)s and a polynucleotide. These nanoparticles allow the rapid and massive separation of particle-containing cells by application of a strong magnetic field. It can also be used as a magnetic resonance contrast for magnetic resonance imaging and tracking of labelled cells, when said cells are used for clinical or live animal research.

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company